Background: Canine obesity is the cause of several health issues, and may predispose other diseases, such as orthopaedic disorders, endocrinopathies, metabolic abnormalities and cardiorespiratory disease which can lead to a decreased quality of life and reduced lifespan. Dog are considered overweight when their body weight is ≥15% above their ideal body weight, and as obese when their body weight exceeds 30% of optimal. Prevalence of canine obesity is estimated to be around 5%–20%, and up to 30%–40% when all overweight dogs are considered. Treatment is based on weight loss programmes, focused on caloric restriction associated with exercise. However, success rate of treatment is low.Objectives: The aim of this study was to investigate the reasons for weight loss failure of obese dogs during treatment with low‐calorie diets.Methods: Records of obese dogs undergoing weight loss programmes between May 2014 and May 2017, assessed by a team specialized in veterinary nutrition, were retrospectively evaluated. Dogs were classified according to weekly weight loss rate (WWLR) (<1%, between 1% and 2%, and more than 2%) and owner compliance with a dietary prescription and physical activity recommendations.Results: The mean WWLR was not satisfactory (<1%) in 64.4% (n = 47/73) of dogs. Regarding owner compliance with the dietary prescription, 44.7% (n = 21/47) of owners did not follow diet prescriptions and physical activity recommendations for their dogs. There was a significant association (p = .01) between compliance of owners and satisfactory weight loss rate; however, there was no association between weight loss success, diet composition sex, reproductive status, age of the dogs and their physical activity (p ≥ .05).Conclusions: Non‐compliance represents a great challenge in the treatment of canine obesity, and may be of more importance than other aspects.

Dogs and cats have differences in vitamin D metabolism compared to other mammalian species, as they are unable to perform vitamin D cutaneous synthesis through sun exposure. Therefore, they are dependent on the dietary intake of this nutrient. The classic functions of vitamin D are to stimulate intestinal calcium and phosphate absorption, renal calcium and phosphate reabsorption and regulate bone mineral metabolism. Thus, it is an important nutrient for calcium and phosphorus homeostasis. This review highlights the evidence of the direct and indirect actions of vitamin D on bone mineral metabolism, the consequences of nutritional imbalances of this nutrient in small animals, as well as differences in vitamin D metabolism between different size dogs.

Background: Obesity is one of the most common nutritional disorders in dogs and cats and is related to the development metabolic comorbidities. Weight loss is the recommended treatment, but success is difficult due to the poor satiety control. Yeast beta-glucans are known as biological modifiers because of their innumerable functions reported in studies with mice and humans, but only one study with dogs was found. This study aimed to evaluate the effects of a diet supplemented with 0.1% beta-glucan on glucose, lipid homeostasis, inflammatory cytokines and satiety parameters in obese dogs. Fourteen dogs composed three experimental groups: Obese group (OG) with seven dogs with body condition score (BCS) 8 or 9; Lean group (LG) included seven non-obese dogs with a BCS of 5; and Supplemented Obese group (SOG) was the OG dogs after 90 days of consumption of the experimental diet. Results: Compared to OG, SOG had lower plasma basal glycemic values (p = 0.05) and reduced serum cholesterol and triglyceride levels. TNF-α was lower in SOG than in OG (p = 0.05), and GLP-1 was increased in SOG compared to OG and LG (p = 0.02). Conclusion: These results are novel and important for recognizing the possibility of using beta-glucan in obesity prevention and treatment.

Obesity is characterized by a low degree of chronic inflammation state that, along with metabolic modifications, promotes important changes in the animal’s organism. Adipose tissue actively participates in inflammation and immunity, and several defense cells of the organism may, therefore, be involved in the diversity found between obese and ideal weight individuals. Studies regarding this subject have shown immune cell changes in humans and rats, however, the literature is scarce in relation to dogs. Thus, the present study aimed to evaluate the gene expression profile of immunoinflammatory response and the lymphoproliferation of obese dogs before and after weight loss. Eight female dogs, neutered, of different breeds, aged between 1 and 8 years (4.74±3.19), obese, with body condition score (BCS) of 9 out of a 9-point scale and body composition determined by the deuterium isotope dilution method were included. The obese dogs were enrolled in a weight loss program and after losing 20% of their initial weight became a second experimental group. A third experimental group consisted of eight female dogs, neutered, aged between 1 and 8 years (3.11±0.78) and with ideal BCS (5 out of a 9-point scale). Gene expression of immunoinflammatory cytokines (resistin, leptin, adiponectin, TNF-α, IL-6, IL-8, and IL-10) was assessed by qRT-PCR and immunity was assessed by lymphoproliferative response using the flow cytometry technique. The data that presented normal distribution was evaluated by analysis of variance by the PROC MIXED of the SAS and when differences were detected, these were compared by the Tukey test. Regarding the gene expression data, the procedure PROC GLIMMIX was adopted and the methodology of generalized linear model was used, in which the Gama distribution proved to be adequate. Values of p<0.05 were considered significant. The mean weight loss period of the animals included in the study was 194.25 ± 28.31 days and the mean weekly weight loss rate was 1.02 ± 0.82%. The average fat mass, both in percentage (P<0.001) and in kilograms (P = 0.012), was higher in the obese group (40.88%; 8.91kg), returning to normal and without difference between the control group (19.16%; 3.01kg) and after weight loss (22.10%; 4.11kg). The weight loss program resulted in an increase in percentage of lean body mass (P = 0.001), 55.50% in obese animals vs 77.90% in obese dogs after weight loss, the latter with no difference when compared to the control group (80.84%). The obese group presented increased gene expression of resistin and IL-8 in relation to the weight loss group (P = 0.002). In adiponectin, the obese group presented increased mRNA gene expression when compared to the weight loss group (P = 0.003). The evaluation of lymphocyte proliferation showed differences between the group of obese animals before and after weight loss (P = 0.004). Weight loss resulted in an increase in the lymphoproliferation rate (18.48%) compared to obese dogs at the beginning of the study (10.71%). These results indicate that weight loss modulates the immunoinflammatory response of obese dogs and may present important benefits to health and longevity of dogs.

Prebiotics promote health benefits, however, there is no consensus on the minimal intake period required in order to obtain good results. This study evaluated the effect of the time of ingestion of prebiotics on fecal fermentation products and immunological features in dogs. Twenty-four adult dogs were randomly distributed in a block design with six groups and four treatments. Diet and intake period were variation factors. Diets were either a control diet without the addition of prebiotic (CO) or with the inclusion of 1% of a commercial product containing a minimum of 0.38% galactooligosaccharides (GOS), 0.5% (B1) or 1% (B2) of a prebiotic blend. Time variable was set at 30 and 60 days for evaluation of immunity and gut health. Results were analyzed in the Statistical Analysis System software (SAS), version 9.4, considering the repeated measures over time design, and means were compared by the Tukey test and p < 0.05 was significant. Propionic acid was the only variable that had an interaction effect, with reduction of this metabolite in treatment B2 in the period of 60 days. At T60, concentrations of immunoglobulin A, lactic acid, and pH in the feces increased (p < 0.05) in all treatments regardless of prebiotic inclusion or not. GOS increased fecal score and lactic acid concentrations. Therefore, a 60-day intake period of a prebiotic blend was not sufficient to modulate fecal and immune variables and higher concentrations of a single prebiotic would be more relevant for results.